(Q53237599)

English

Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway.

scientific article published on 25 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

reactive oxygen species

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jin Young Sung

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

Hyoung Chul Choi

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

publication date

25 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

Vascular Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

56

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

1-2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

1-8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Antioxidant activity of different dihydropyridines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

The AMP-activated protein kinase pathway--new players upstream and downstream.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Calcium channels in vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Pharmacology of smooth muscle cell replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Mechanism of antiatherogenic action of calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

SOXF: redox mediators of vascular smooth muscle cell growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Ca(2+) signaling, genes and the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Intracellular Ca2+ pool content is linked to control of cell growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Dual mechanism of action of amlodipine in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Wnt4/β-Catenin Signaling Induces VSMC Proliferation and Is Associated With Intimal Thickening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Arterial aging: a journey into subclinical arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2011.06.001

7 January 2021

Identifiers

10.1016/J.VPH.2011.06.001

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21708289

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53237599&oldid=1518787706"